Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes

被引:117
作者
Cano-Garrido, Olivia [1 ,2 ,3 ]
Seras-Franzoso, Joaquin [1 ,2 ,3 ]
Garcia-Fruitos, Elena [1 ,2 ,3 ]
机构
[1] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Cerdanyola Del, Spain
[2] Univ Autonoma Barcelona, Dept Genet & Microbiol, Bellaterra 08193, Cerdanyola Del, Spain
[3] CIBER BBN, Bellaterra 08193, Cerdanyola Del, Spain
来源
MICROBIAL CELL FACTORIES | 2015年 / 14卷
关键词
Lactic acid bacteria; Delivery vector; QPS; Mucosal; Therapy; Treatment; MODIFIED LACTOCOCCUS-LACTIS; TOXIN FRAGMENT-C; CONTROLLED GENE-EXPRESSION; ABERRANT CRYPT FOCI; LACTOBACILLUS-CASEI; ORAL IMMUNIZATION; IMMUNE-RESPONSES; COLORECTAL-CANCER; THERAPEUTIC MOLECULES; BACILLUS-SUBTILIS;
D O I
10.1186/s12934-015-0313-6
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Lactic acid bacteria (LAB) have a long history of safe exploitation by humans, being used for centuries in food production and preservation and as probiotic agents to promote human health. Interestingly, some species of these Gram-positive bacteria, which are generally recognized as safe organisms by the US Food and Drug Administration (FDA), are able to survive through the gastrointestinal tract (GIT), being capable to reach and colonize the intestine, where they play an important role. Besides, during the last decades, an important effort has been done for the development of tools to use LAB as microbial cell factories for the production of proteins of interest. Given the need to develop effective strategies for the delivery of prophylactic and therapeutic molecules, LAB have appeared as an appealing option for the oral, intranasal and vaginal delivery of such molecules. So far, these genetically modified organisms have been successfully used as vehicles for delivering functional proteins to mucosal tissues in the treatment of many different pathologies including GIT related pathologies, diabetes, cancer and viral infections, among others. Interestingly, the administration of such microorganisms would suppose a significant decrease in the production cost of the treatments agents since being live organisms, such vectors would be able to autonomously amplify and produce and deliver the protein of interest. In this context, this review aims to provide an overview of the use of LAB engineered as a promising alternative as well as a safety delivery platform of recombinant proteins for the treatment of a wide range of diseases.
引用
收藏
页数:12
相关论文
共 115 条
  • [1] Oral Delivery of Glucagon Like Peptide-1 by a Recombinant Lactococcus lactis
    Agarwal, Payal
    Khatri, Pulkit
    Billack, Blase
    Low, Woon-Kai
    Shao, Jun
    [J]. PHARMACEUTICAL RESEARCH, 2014, 31 (12) : 3404 - 3414
  • [2] Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
    Aggarwal, Bharat B.
    Vijayalekshmi, R. V.
    Sung, Bokyung
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (02) : 425 - 430
  • [3] Genetically Engineered Lactococcus lactis Protect against House Dust Mite Allergy in a BALB/c Mouse Model
    Ai, Chunqing
    Zhang, Qiuxiang
    Ren, Chengcheng
    Wang, Gang
    Liu, Xiaoming
    Tian, Fengwei
    Zhao, Jianxin
    Zhang, Hao
    Chen, Yong Q.
    Chen, Wei
    [J]. PLOS ONE, 2014, 9 (10):
  • [4] Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats
    An, Hyang Mi
    Park, Shin Young
    Lee, Do Kyung
    Kim, Jung Rae
    Cha, Min Kyeong
    Lee, Si Won
    Lim, Hyung Taeck
    Kim, Kyung Jae
    Ha, Nam Joo
    [J]. LIPIDS IN HEALTH AND DISEASE, 2011, 10
  • [5] In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli
    Andersen, Kasper Krogh
    Marcotte, Harold
    Alvarez, Beatriz
    Boyaka, Prosper N.
    Hammarstrom, Lennart
    [J]. BMC BIOTECHNOLOGY, 2011, 11
  • [6] The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?
    Azcarate-Peril, M. Andrea
    Sikes, Michael
    Bruno-Barcena, Jose M.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2011, 301 (03): : G401 - G424
  • [7] Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer
    Baek, J. O.
    Seo, J. W.
    Kwon, O.
    Park, S. M.
    Kim, C. H.
    Kim, I. H.
    [J]. ENZYME AND MICROBIAL TECHNOLOGY, 2012, 50 (03) : 173 - 180
  • [8] Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins
    Bahey-El-Din, Mohammed
    Gahan, Cormac G. M.
    Griffin, Brendan T.
    [J]. CURRENT GENE THERAPY, 2010, 10 (01) : 34 - 45
  • [9] Gastroenterology 1 - Inflammatory bowel disease: cause and immunobiology
    Baumgart, Daniel C.
    Carding, Simon R.
    [J]. LANCET, 2007, 369 (9573) : 1627 - 1640
  • [10] Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces
    Benbouziane, Bouasria
    Ribelles, Pedro
    Aubry, Camille
    Martin, Rebeca
    Kharrat, Pascale
    Riazi, Ali
    Langella, Philippe
    Bermudez-Humaran, Luis G.
    [J]. JOURNAL OF BIOTECHNOLOGY, 2013, 168 (02) : 120 - 129